Can the vogue of decentralized trials continue beyond the pandemic?

Decentralizing clinical trials has become a must-do rather than nice-to-have during the pandemic, with hospital shutdowns and restricted access disrupting company programs and putting enrolled patients at risk. But a range of logistical challenges need to be solved before the trials become mainstream.

The idea of decentralizing clinical trials has long been attractive for its ability to reduce dependence on major academic medical centers and encompass a broader swath of patients. ...